Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID‐19

BackgroundThe broad‐spectrum antifungal isavuconazole is administered to treat invasive aspergillosis and mucormycosis.ObjectivesIsavuconazole plasma concentrations in critically ill ICU patients with or without COVID‐19 and invasive fungal infection were determined, and factors for sub‐therapeutic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mycoses 2023-12, Vol.66 (12), p.1071-1078
Hauptverfasser: Bertram, Ralph, Naumann, Hans‐Theodor, Bartsch, Vanessa, Hitzl, Wolfgang, Kinzig, Martina, Haarmeyer, Golo‐Sung, Baumgärtel, Matthias, Geise, Arnim, Muschner, Dorothea, Nentwich, Jens, John, Stefan, Sörgel, Fritz, Steinmann, Joerg, Höhl, Rainer
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1078
container_issue 12
container_start_page 1071
container_title Mycoses
container_volume 66
creator Bertram, Ralph
Naumann, Hans‐Theodor
Bartsch, Vanessa
Hitzl, Wolfgang
Kinzig, Martina
Haarmeyer, Golo‐Sung
Baumgärtel, Matthias
Geise, Arnim
Muschner, Dorothea
Nentwich, Jens
John, Stefan
Sörgel, Fritz
Steinmann, Joerg
Höhl, Rainer
description BackgroundThe broad‐spectrum antifungal isavuconazole is administered to treat invasive aspergillosis and mucormycosis.ObjectivesIsavuconazole plasma concentrations in critically ill ICU patients with or without COVID‐19 and invasive fungal infection were determined, and factors for sub‐therapeutic drug levels ( 25 (p = .006), SOFA score > 12 (p = .026), RRT (p = .017) and ECMO requirement (p = .001).ConclusionsIsavuconazole plasma levels can be negatively affected by patients' risk factors, supportive renal replacement and ECMO therapy. Future prospective studies analysing the relevance of isavuconazole drug levels in ICU patient outcome are urgently needed.
doi_str_mv 10.1111/myc.13653
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2864617785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2884960725</sourcerecordid><originalsourceid>FETCH-LOGICAL-c325t-2bdf6c26a0d8d54572d5d9530a48377db1bb30c355f083d747d03465bd8cf6fd3</originalsourceid><addsrcrecordid>eNpdkbtOwzAARS0EEqUw8AeWWGBIsePYTkZUXpUqsQBr5PjRunLjYjtFZYFP4Bv5EtKWibvc5ejqSgeAc4xGuM_1ciNHmDBKDsAAF6TKEEX8EAxQRUjGC8SPwUmMC4Qwr3I2AJ9jZ1srhYOiVVDppZ8FsZpbCY2QyYcIhTFaJtvOYAq-m82h02vtIvQG2ijWnfSt-PBOQ9tCGWzajrkNtM7BlUhWtynCd5vm0Idd-y7B8dPr5Pbn6xtXp-DICBf12V8Pwcv93fP4MZs-PUzGN9NMkpymLG-UYTJnAqlS0YLyXFFVUYJEURLOVYObhiBJKDWoJIoXXCFSMNqoUhpmFBmCy_3uKvi3TsdUL22U2jnRat_FOi9ZwTDnJe3Ri3_owneh7d_1VFlUDPF8S13tKRl8jEGbehXsUoRNjVG9VVH3KuqdCvILhi5-EA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2884960725</pqid></control><display><type>article</type><title>Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID‐19</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Bertram, Ralph ; Naumann, Hans‐Theodor ; Bartsch, Vanessa ; Hitzl, Wolfgang ; Kinzig, Martina ; Haarmeyer, Golo‐Sung ; Baumgärtel, Matthias ; Geise, Arnim ; Muschner, Dorothea ; Nentwich, Jens ; John, Stefan ; Sörgel, Fritz ; Steinmann, Joerg ; Höhl, Rainer</creator><creatorcontrib>Bertram, Ralph ; Naumann, Hans‐Theodor ; Bartsch, Vanessa ; Hitzl, Wolfgang ; Kinzig, Martina ; Haarmeyer, Golo‐Sung ; Baumgärtel, Matthias ; Geise, Arnim ; Muschner, Dorothea ; Nentwich, Jens ; John, Stefan ; Sörgel, Fritz ; Steinmann, Joerg ; Höhl, Rainer</creatorcontrib><description>BackgroundThe broad‐spectrum antifungal isavuconazole is administered to treat invasive aspergillosis and mucormycosis.ObjectivesIsavuconazole plasma concentrations in critically ill ICU patients with or without COVID‐19 and invasive fungal infection were determined, and factors for sub‐therapeutic drug levels (&lt;1 μg/mL) were evaluated.Patients and MethodsIsavuconazole plasma levels were measured as part of therapeutic drug monitoring (TDM) in ICUs of a tertiary hospital. Concentrations determined 20–28 h after previous dosing were defined as trough (Cmin) levels. A total of 160 Cmin levels from 62 patients with invasive fungal infections were analysed, 30 of which suffering from COVID‐19. Patient characteristics included into univariable and multivariable analyses were gender, age, COVID‐19 status, body mass index (BMI), sepsis‐related organ failure (SOFA) score, renal replacement therapy (RRT) and extracorporeal membrane oxygenation (ECMO) requirement.ResultsThe mean Cmin of isavuconazole in all patients was 1.64 μg/mL (interquartile range 0.83–2.24 μg/mL, total range 0.24–5.67 μg/mL). In total, 34.4% of the Cmin values (corresponding to 46.8% of patients) were below a threshold concentration of 1 μg/mL. Drug concentrations between patients with or without COVID‐19 did not differ (p = .43). In contrast, levels were significantly lower in patients with female sex (p = .0007), age ≤ 65 years (p = .002), BMI &gt; 25 (p = .006), SOFA score &gt; 12 (p = .026), RRT (p = .017) and ECMO requirement (p = .001).ConclusionsIsavuconazole plasma levels can be negatively affected by patients' risk factors, supportive renal replacement and ECMO therapy. Future prospective studies analysing the relevance of isavuconazole drug levels in ICU patient outcome are urgently needed.</description><identifier>ISSN: 0933-7407</identifier><identifier>EISSN: 1439-0507</identifier><identifier>DOI: 10.1111/myc.13653</identifier><language>eng</language><publisher>Berlin: Wiley Subscription Services, Inc</publisher><subject>Aspergillosis ; Body mass index ; COVID-19 ; Extracorporeal membrane oxygenation ; Mucormycosis ; Patients ; Plasma levels ; Renal failure ; Risk factors ; Sepsis</subject><ispartof>Mycoses, 2023-12, Vol.66 (12), p.1071-1078</ispartof><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c325t-2bdf6c26a0d8d54572d5d9530a48377db1bb30c355f083d747d03465bd8cf6fd3</citedby><cites>FETCH-LOGICAL-c325t-2bdf6c26a0d8d54572d5d9530a48377db1bb30c355f083d747d03465bd8cf6fd3</cites><orcidid>0000-0001-6681-9703 ; 0000-0001-6381-8991 ; 0000-0003-0654-6381 ; 0000-0001-6029-2103 ; 0000-0002-1902-7356 ; 0000-0002-7696-1479 ; 0000-0003-2983-0887 ; 0000-0002-3181-3667</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Bertram, Ralph</creatorcontrib><creatorcontrib>Naumann, Hans‐Theodor</creatorcontrib><creatorcontrib>Bartsch, Vanessa</creatorcontrib><creatorcontrib>Hitzl, Wolfgang</creatorcontrib><creatorcontrib>Kinzig, Martina</creatorcontrib><creatorcontrib>Haarmeyer, Golo‐Sung</creatorcontrib><creatorcontrib>Baumgärtel, Matthias</creatorcontrib><creatorcontrib>Geise, Arnim</creatorcontrib><creatorcontrib>Muschner, Dorothea</creatorcontrib><creatorcontrib>Nentwich, Jens</creatorcontrib><creatorcontrib>John, Stefan</creatorcontrib><creatorcontrib>Sörgel, Fritz</creatorcontrib><creatorcontrib>Steinmann, Joerg</creatorcontrib><creatorcontrib>Höhl, Rainer</creatorcontrib><title>Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID‐19</title><title>Mycoses</title><description>BackgroundThe broad‐spectrum antifungal isavuconazole is administered to treat invasive aspergillosis and mucormycosis.ObjectivesIsavuconazole plasma concentrations in critically ill ICU patients with or without COVID‐19 and invasive fungal infection were determined, and factors for sub‐therapeutic drug levels (&lt;1 μg/mL) were evaluated.Patients and MethodsIsavuconazole plasma levels were measured as part of therapeutic drug monitoring (TDM) in ICUs of a tertiary hospital. Concentrations determined 20–28 h after previous dosing were defined as trough (Cmin) levels. A total of 160 Cmin levels from 62 patients with invasive fungal infections were analysed, 30 of which suffering from COVID‐19. Patient characteristics included into univariable and multivariable analyses were gender, age, COVID‐19 status, body mass index (BMI), sepsis‐related organ failure (SOFA) score, renal replacement therapy (RRT) and extracorporeal membrane oxygenation (ECMO) requirement.ResultsThe mean Cmin of isavuconazole in all patients was 1.64 μg/mL (interquartile range 0.83–2.24 μg/mL, total range 0.24–5.67 μg/mL). In total, 34.4% of the Cmin values (corresponding to 46.8% of patients) were below a threshold concentration of 1 μg/mL. Drug concentrations between patients with or without COVID‐19 did not differ (p = .43). In contrast, levels were significantly lower in patients with female sex (p = .0007), age ≤ 65 years (p = .002), BMI &gt; 25 (p = .006), SOFA score &gt; 12 (p = .026), RRT (p = .017) and ECMO requirement (p = .001).ConclusionsIsavuconazole plasma levels can be negatively affected by patients' risk factors, supportive renal replacement and ECMO therapy. Future prospective studies analysing the relevance of isavuconazole drug levels in ICU patient outcome are urgently needed.</description><subject>Aspergillosis</subject><subject>Body mass index</subject><subject>COVID-19</subject><subject>Extracorporeal membrane oxygenation</subject><subject>Mucormycosis</subject><subject>Patients</subject><subject>Plasma levels</subject><subject>Renal failure</subject><subject>Risk factors</subject><subject>Sepsis</subject><issn>0933-7407</issn><issn>1439-0507</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpdkbtOwzAARS0EEqUw8AeWWGBIsePYTkZUXpUqsQBr5PjRunLjYjtFZYFP4Bv5EtKWibvc5ejqSgeAc4xGuM_1ciNHmDBKDsAAF6TKEEX8EAxQRUjGC8SPwUmMC4Qwr3I2AJ9jZ1srhYOiVVDppZ8FsZpbCY2QyYcIhTFaJtvOYAq-m82h02vtIvQG2ijWnfSt-PBOQ9tCGWzajrkNtM7BlUhWtynCd5vm0Idd-y7B8dPr5Pbn6xtXp-DICBf12V8Pwcv93fP4MZs-PUzGN9NMkpymLG-UYTJnAqlS0YLyXFFVUYJEURLOVYObhiBJKDWoJIoXXCFSMNqoUhpmFBmCy_3uKvi3TsdUL22U2jnRat_FOi9ZwTDnJe3Ri3_owneh7d_1VFlUDPF8S13tKRl8jEGbehXsUoRNjVG9VVH3KuqdCvILhi5-EA</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Bertram, Ralph</creator><creator>Naumann, Hans‐Theodor</creator><creator>Bartsch, Vanessa</creator><creator>Hitzl, Wolfgang</creator><creator>Kinzig, Martina</creator><creator>Haarmeyer, Golo‐Sung</creator><creator>Baumgärtel, Matthias</creator><creator>Geise, Arnim</creator><creator>Muschner, Dorothea</creator><creator>Nentwich, Jens</creator><creator>John, Stefan</creator><creator>Sörgel, Fritz</creator><creator>Steinmann, Joerg</creator><creator>Höhl, Rainer</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6681-9703</orcidid><orcidid>https://orcid.org/0000-0001-6381-8991</orcidid><orcidid>https://orcid.org/0000-0003-0654-6381</orcidid><orcidid>https://orcid.org/0000-0001-6029-2103</orcidid><orcidid>https://orcid.org/0000-0002-1902-7356</orcidid><orcidid>https://orcid.org/0000-0002-7696-1479</orcidid><orcidid>https://orcid.org/0000-0003-2983-0887</orcidid><orcidid>https://orcid.org/0000-0002-3181-3667</orcidid></search><sort><creationdate>20231201</creationdate><title>Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID‐19</title><author>Bertram, Ralph ; Naumann, Hans‐Theodor ; Bartsch, Vanessa ; Hitzl, Wolfgang ; Kinzig, Martina ; Haarmeyer, Golo‐Sung ; Baumgärtel, Matthias ; Geise, Arnim ; Muschner, Dorothea ; Nentwich, Jens ; John, Stefan ; Sörgel, Fritz ; Steinmann, Joerg ; Höhl, Rainer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c325t-2bdf6c26a0d8d54572d5d9530a48377db1bb30c355f083d747d03465bd8cf6fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aspergillosis</topic><topic>Body mass index</topic><topic>COVID-19</topic><topic>Extracorporeal membrane oxygenation</topic><topic>Mucormycosis</topic><topic>Patients</topic><topic>Plasma levels</topic><topic>Renal failure</topic><topic>Risk factors</topic><topic>Sepsis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bertram, Ralph</creatorcontrib><creatorcontrib>Naumann, Hans‐Theodor</creatorcontrib><creatorcontrib>Bartsch, Vanessa</creatorcontrib><creatorcontrib>Hitzl, Wolfgang</creatorcontrib><creatorcontrib>Kinzig, Martina</creatorcontrib><creatorcontrib>Haarmeyer, Golo‐Sung</creatorcontrib><creatorcontrib>Baumgärtel, Matthias</creatorcontrib><creatorcontrib>Geise, Arnim</creatorcontrib><creatorcontrib>Muschner, Dorothea</creatorcontrib><creatorcontrib>Nentwich, Jens</creatorcontrib><creatorcontrib>John, Stefan</creatorcontrib><creatorcontrib>Sörgel, Fritz</creatorcontrib><creatorcontrib>Steinmann, Joerg</creatorcontrib><creatorcontrib>Höhl, Rainer</creatorcontrib><collection>CrossRef</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Mycoses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bertram, Ralph</au><au>Naumann, Hans‐Theodor</au><au>Bartsch, Vanessa</au><au>Hitzl, Wolfgang</au><au>Kinzig, Martina</au><au>Haarmeyer, Golo‐Sung</au><au>Baumgärtel, Matthias</au><au>Geise, Arnim</au><au>Muschner, Dorothea</au><au>Nentwich, Jens</au><au>John, Stefan</au><au>Sörgel, Fritz</au><au>Steinmann, Joerg</au><au>Höhl, Rainer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID‐19</atitle><jtitle>Mycoses</jtitle><date>2023-12-01</date><risdate>2023</risdate><volume>66</volume><issue>12</issue><spage>1071</spage><epage>1078</epage><pages>1071-1078</pages><issn>0933-7407</issn><eissn>1439-0507</eissn><abstract>BackgroundThe broad‐spectrum antifungal isavuconazole is administered to treat invasive aspergillosis and mucormycosis.ObjectivesIsavuconazole plasma concentrations in critically ill ICU patients with or without COVID‐19 and invasive fungal infection were determined, and factors for sub‐therapeutic drug levels (&lt;1 μg/mL) were evaluated.Patients and MethodsIsavuconazole plasma levels were measured as part of therapeutic drug monitoring (TDM) in ICUs of a tertiary hospital. Concentrations determined 20–28 h after previous dosing were defined as trough (Cmin) levels. A total of 160 Cmin levels from 62 patients with invasive fungal infections were analysed, 30 of which suffering from COVID‐19. Patient characteristics included into univariable and multivariable analyses were gender, age, COVID‐19 status, body mass index (BMI), sepsis‐related organ failure (SOFA) score, renal replacement therapy (RRT) and extracorporeal membrane oxygenation (ECMO) requirement.ResultsThe mean Cmin of isavuconazole in all patients was 1.64 μg/mL (interquartile range 0.83–2.24 μg/mL, total range 0.24–5.67 μg/mL). In total, 34.4% of the Cmin values (corresponding to 46.8% of patients) were below a threshold concentration of 1 μg/mL. Drug concentrations between patients with or without COVID‐19 did not differ (p = .43). In contrast, levels were significantly lower in patients with female sex (p = .0007), age ≤ 65 years (p = .002), BMI &gt; 25 (p = .006), SOFA score &gt; 12 (p = .026), RRT (p = .017) and ECMO requirement (p = .001).ConclusionsIsavuconazole plasma levels can be negatively affected by patients' risk factors, supportive renal replacement and ECMO therapy. Future prospective studies analysing the relevance of isavuconazole drug levels in ICU patient outcome are urgently needed.</abstract><cop>Berlin</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/myc.13653</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6681-9703</orcidid><orcidid>https://orcid.org/0000-0001-6381-8991</orcidid><orcidid>https://orcid.org/0000-0003-0654-6381</orcidid><orcidid>https://orcid.org/0000-0001-6029-2103</orcidid><orcidid>https://orcid.org/0000-0002-1902-7356</orcidid><orcidid>https://orcid.org/0000-0002-7696-1479</orcidid><orcidid>https://orcid.org/0000-0003-2983-0887</orcidid><orcidid>https://orcid.org/0000-0002-3181-3667</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0933-7407
ispartof Mycoses, 2023-12, Vol.66 (12), p.1071-1078
issn 0933-7407
1439-0507
language eng
recordid cdi_proquest_miscellaneous_2864617785
source Wiley Online Library Journals Frontfile Complete
subjects Aspergillosis
Body mass index
COVID-19
Extracorporeal membrane oxygenation
Mucormycosis
Patients
Plasma levels
Renal failure
Risk factors
Sepsis
title Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID‐19
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A56%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20demographic%20factors%20affecting%20trough%20levels%20of%20isavuconazole%20in%20critically%20ill%20patients%20with%20or%20without%20COVID%E2%80%9019&rft.jtitle=Mycoses&rft.au=Bertram,%20Ralph&rft.date=2023-12-01&rft.volume=66&rft.issue=12&rft.spage=1071&rft.epage=1078&rft.pages=1071-1078&rft.issn=0933-7407&rft.eissn=1439-0507&rft_id=info:doi/10.1111/myc.13653&rft_dat=%3Cproquest_cross%3E2884960725%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2884960725&rft_id=info:pmid/&rfr_iscdi=true